Persistence with intravenous zoledronate in elderly patients with osteoporosis

Osteoporosis International

Volumn 23, Issue 9, 2012, Pages 2329-2333

  Lee, Y K ^a   Nho, J H ^a   Ha, Y C ^b   Koo, K H ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

Author keywords

Adherence; Osteoporosis; Persistence; Treatment; Zoledronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ZOLEDRONIC ACID;

AGED; ARTHRALGIA; ARTICLE; CONSULTATION; DRUG COST; DRUG WITHDRAWAL; FEMALE; FEVER; FLU LIKE SYNDROME; GERIATRIC PATIENT; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; OSTEOPOROSIS; OUTPATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT REFUSAL;

AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MALE; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUESTIONNAIRES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84867098176     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1881-x     Document Type: Article

References (10)

1. Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, Jonsson B, Pols H, Cramer JA (2007) Non-compliance: The Achilles' heel of anti-fracture efficacy. Osteoporos Int 18:711-719 (Pubitemid 46684777)
2. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003-1008 (Pubitemid 40064656)
3. Compston JE, Seeman E (2006) Compliance with osteoporosis therapy is the weakest link. Lancet 368:973-974 (Pubitemid 44353676)
4. Boonen S, Vanderschueren D, Venken K, Milisen K, Delforge M, Haentjens P (2008) Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: Enhanced efficacy by enhanced compliance. J Intern Med 264:315-332
5. Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023-1031 (Pubitemid 47019996)
6. Kamatari M, Koto S, Ozawa N, Urao C, Suzuki Y, Akasaka E, Yanagimoto K, Sakota K (2007) Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: Alendronate and risedronate. J Bone Miner Metab 25:302-309 (Pubitemid 47283269)
7. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Brookhart MA (2005) Compliance with osteoporosis medications. Arch Intern Med 165:2414-2419 (Pubitemid 41640855)
8. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022 (Pubitemid 44175011)
9. Kertes J, Dushenat M, Vesterman JL, Lemberger J, Bregman J, Friedman N (2008) Factors contributing to compliance with osteoporosis medication. Isr Med Assoc J 10:207-213 (Pubitemid 351649619)
10. Weycker D, Macarios D, Edelsberg J, Oster G (2007) Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 18:271-277 (Pubitemid 46233172)